Skip to main content

Treatment preferences and the selection of acute migraine medications: results from a population-based survey

Abstract

Seven oral triptans are available for treating acute migraine. We surveyed US migraine sufferers on the relative importance of treatment attributes for choosing among oral triptans. A multiattribute decision model was used to combine data on the relative importance of efficacy, consistency, and tolerability of acute treatment (determined by 206 triptan-experienced and 209 triptannaive subjects) with data on the performance of the triptans across the attributes (derived from a recent meta-analysis). Efficacy was considered significantly more important than tolerability and consistency: tolerability was significantly more important than consistency for triptan- naive but not triptan-experienced subjects. The multiattribute decision model found that almotriptan, eletriptan, and rizatriptan were significantly closer to the hypothetical ideal triptan than the reference product, sumatriptan 100 mg, for both triptan-naive and triptan-experienced migraine sufferers. Almotriptan, eletriptan, and rizatriptan were the preferred triptans selected on the basis of patients’ own priorities and product performance data.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Richard B. Lipton.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lipton, R.B., Liberman, J., Cutrer, F.M. et al. Treatment preferences and the selection of acute migraine medications: results from a population-based survey. J Headache Pain 5, 123–130 (2004). https://doi.org/10.1007/s10194-004-0080-y

Download citation

Key words

  • Meta-analysis
  • Migraine
  • Surveys
  • Treatment attributes
  • TRIPSTAR
  • Triptans
\